Brief: Acer Therapeutics Announces ACER-801 IND Clearance For The Treatment Of Induced Vasomotor Symptoms
09/12/2021 13:59
Dec 9 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ANNOUNCES ACER-801 IND CLEARANCE FOR THE
TREATMENT OF INDUCED VASOMOTOR SYMPTOMS
* ACER THERAPEUTICS INC - PHASE 2A TRIAL IS EXPECTED TO
BEGIN IN
Q1 2022, SUBJECT TO ADDITIONAL CAPITAL REQUIRED FOR ACER-801
CLINICAL DEVELOPMENT
Source text for Eikon: ID:nGNXb9wf41
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31